The global ulcerative colitis market size, valued at USD 13.0 billion in 2025, is projected to reach USD 14.0 billion in 2026 and USD 25.7 billion by 2035, representing a CAGR of 7.0% during the forecast period 2026 to 2035. Based on route of administration, the subcutaneous route dominates (more than 40%) the current market; this trend is unlikely to change in the future. With respect to distribution channels, hospital pharmacies are expected to capture most of the future ulcerative colitis mar...

The global Crohn’s disease market size, valued at USD 9.6 billion in 2025, is projected to reach USD 10.3 billion in 2026 and USD 18.1 billion by 2035, representing a CAGR of 6.5% during the forecast period 2026 to 2035. Based on the route of administration, the subcutaneous route dominates (more than 40%) the future market (2035). The rising prevalence of Crohn’s disease represents a major market opportunity within this domain. Notably, in 2023, an estimated 1 million patients were living w...

The global large volume wearable injectors market, valued at USD 12.6 billion in 2025, is projected to reach USD 16.4 billion in 2026 and USD 31.4 billion by 2035, representing a CAGR of 7.5% during the forecast period 2026 to 2035. The market numbers have been calculated by taking into account the revenues generated through sales of large volume wearable injectors and related drug-device combination products. Based on market share distribution by therapeutic area, devices used to treat autoimmu...

The global PERK inhibitors market is envisaged to rise from USD 46.0 million in 2026 and is projected to reach USD 450.0 million by 2040, growing at a CAGR of 17.7% over the forecast period 2026 to 2040, driven by Phase 1b oncology combination development and research-enablement demand. Based on product / offering type, therapeutic drug candidates is both the dominant and fastest-growing category, holding 34.0% share in 2026 and expanding at 21.3% CAGR through 2040, driven by oncology pipeline v...

The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market. In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, includin...

The global bacteriophage therapy market, valued at USD 58.1 million in 2025, is projected to reach USD 66.5 million in 2026 and USD 266.8 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. In terms of target indication, urinary tract infections hold the highest (around 30%) share of the current market. With respect to route of administration, oral route dominates the current market.

The Europe cancer metabolism based therapeutics market, valued at USD 0.82 billion in 2025, is projected to reach USD 1.12 billion in 2026 and USD 8.54 billion by 2035, with a CAGR of 25.3% during the forecast period 2026 to 2035. In terms of type of modality, small molecules are expected to account for the largest market share in 2026; this trend is unlikely to change in the future. With respect to route of administration, oral route (close to 85%) is expected to dominate the market in 2035. Th...

The global automated rapid microbiology testing platforms market, valued at USD 48.7 million in 2025, is projected to reach USD 51.7 million in 2026 and USD 108.7 million by 2035, representing a CAGR of 8.6% during the forecast period 2026 to 2035. In terms of type of modality, biologics accounts for the highest share (over 60%) of the current market. With respect to type of offering, consumables dominate the current market.

The global idiopathic short stature market is expected to rise from USD 1.85 billion in 2026 to reach USD 5.08 billion by 2040, growing at a CAGR of 7.48% over the forecast period 2026 to 2040, driven by weekly growth hormone adoption, home-based treatment, and genetic reclassification of short stature. Based on Geography, North America captures 45.0% market share in 2026, whereas Asia-Pacific registers a 10.2% CAGR through 2040, driven by faster private endocrine care expansion. Based on Therap...

The global Duchenne muscular dystrophy market reached USD 5.2 billion in 2026 and is projected to reach USD 28.7 billion by 2040, growing at a CAGR of 13.0% over the forecast period 2026 to 2040, driven by mutation-targeted therapies, gene transfer adoption, and broader rare-disease reimbursement. Based on therapy class, gene therapies capture 34.0% market share in 2026, whereas cell therapies register a 28.4% CAGR through 2040, driven by late-stage cardiac and skeletal-muscle programs. Based on...

The North America non-viral transfection reagents market, valued at USD 0.31 billion in 2025, is projected to reach USD 0.34 billion in 2026 and USD 0.70 billion by 2035, representing a CAGR of 8.5% during the forecast period 2026 to 2035. Non-viral transfection reagents have become integral to modern molecular biology and therapeutic development, offering reliable and scalable alternatives to viral vectors for delivering nucleic acids into cells. The chemical and physical transfection approache...

The global cloud based drug discovery platforms market, valued at USD 3.7 billion in 2025, is projected to reach USD 4.2 billion in 2026 and USD 11.4 billion by 2035, representing a CAGR of 11.7% during the forecast period 2026 to 2035. Cloud based drug discovery platforms are centralized, internet-hosted software ecosystems that provide scalable computing power, data storage, and advanced analytics tools to accelerate the discovery of new therapeutic compounds. According to our projections, Nor...

The Europe non-viral transfection reagents market, valued at USD 0.22 billion in 2025, is projected to reach USD 0.24 billion in 2026 and USD 0.40 billion by 2035, representing a CAGR of 5.7% during the forecast period 2026-2035. Non-viral transfection reagents refer to chemical or physical delivery systems that introduce nucleic acids, including DNA, RNA, mRNA, siRNA, and gene editing components, into target cells without relying on viral vectors. In addition, rising investment in nucleic acid-...

The wearable injectors market, valued at USD 6.5 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 13.0 billion by 2035, representing a CAGR of 7.4% during the forecast period 2026 to 2035. Please note that the total wearable injectors market includes the sum of both insulin and non insulin drugs market. In terms of type of device, currently, the infusion pumps hold the highest share (more than 90%) of the insulin pumps market. The global surge in chronic disorders, such as...

The global CRISPR based therapeutics market, valued at USD 0.1 billion in 2025, is projected to reach USD 0.2 billion in 2026 and USD 6.3 billion by 2035, with a CAGR of 43.8% during the forecast period 2026 to 2035. The CRISPR domain has evolved from basic scientific research into an important area of advanced therapeutics. Notably, the in vivo therapies segment is expected to grow at a significant pace during the forecast period due to rapid advancements in targeted gene-editing delivery techn...

The global RNAi technology market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.8 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 14.0% during the forecast period 2026 to 2035. RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses disease-causing genes at the messenger RNA (mRNA) level. Initially developed as a research tool, RNAi has evolved into a clinically validated therapeutic platform. Currently, the siRNA segment...

The global AI in clinical trials market, valued at USD 3.48 billion in 2025, is projected to reach USD 3.96 billion in 2026 and USD 11.61 billion by 2035, representing a CAGR of 12.7% during the forecast period 2026 to 2035. Based on the deployment mode, cloud-based AI solutions capture the largest share (around 75%) of the current market, and the trend is unlikely to change in the future. In terms of therapeutic areas, oncological disorders are expected to hold the largest market share (more th...

The global next generation contact lenses and visual prostheses market, valued at USD 0.36 billion in 2024, is projected to reach USD 0.60 billion in 2025 and USD 16.97 billion by 2035, representing a CAGR of 39.7% during the forecast period. It is worth highlighting here that there is a rapid increase witnessed in the number of blind and partially sighted individuals. According to the National Eye Institute, nearly 1.3 million people are blind, while 2.9 million individuals have poor vision, in...

The global surgical robots market, valued at USD 9.8 billion in 2025, is projected to reach USD 10.6 billion in 2026 and USD 22.9 billion by 2035, with a 8.9% CAGR during the forecast period 2026 to 2035. In terms of geography, North America captures the majority of the market share.

The global cell therapy manufacturing market, valued at USD 6.3 billion in 2025, is projected to reach USD 7.2 billion in 2026 and USD 14.0 billion by 2035, representing a CAGR of 7.7% during the forecast period 2026 to 2035. Researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities across the globe. Further, several...